Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.
about
Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic ApproachesSoluble oligomers of the amyloid beta-protein impair synaptic plasticity and behaviorValsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer diseaseDisrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal modelsInteraction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanismsEPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaquesCurrent and future implications of basic and translational research on amyloid-β peptide production and removal pathwaysModulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanismsXanthene food dye, as a modulator of Alzheimer's disease amyloid-beta peptide aggregation and the associated impaired neuronal cell function.Halogenation generates effective modulators of amyloid-Beta aggregation and neurotoxicity.Effects of Neurotrophic Support and Amyloid-Targeted Combined Therapy on Adult Hippocampal Neurogenesis in a Transgenic Model of Alzheimer's DiseaseSodium/myo-Inositol transporters: substrate transport requirements and regional brain expression in the TgCRND8 mouse model of amyloid pathologyAmyloid β-Protein Assembly: The Effect of Molecular Tweezers CLR01 and CLR03Investigational drugs for treating agitation in persons with dementia.A safe, blood-brain barrier permeable triphenylmethane dye inhibits amyloid-β neurotoxicity by generating nontoxic aggregatesC-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity.Alpha-helix targeting reduces amyloid-beta peptide toxicity.Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease.Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease.Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration.Carvedilol as a potential novel agent for the treatment of Alzheimer's disease.Combination therapy in a transgenic model of Alzheimer's disease.Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors.Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models.Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's diseaseA new-generation of Bacillus subtilis cell factory for further elevated scyllo-inositol production.Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice.An update on the amyloid hypothesis.Targeting Abeta and tau in Alzheimer's disease, an early interim reportUpdate on the pharmacological treatment of Alzheimer's diseaseGenome-wide analysis of Saccharomyces cerevisiae identifies cellular processes affecting intracellular aggregation of Alzheimer's amyloid-β42: importance of lipid homeostasis.Development and validation of a yeast high-throughput screen for inhibitors of Aβ₄₂ oligomerization.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trialsMechanisms of small-molecule binding to intrinsically disordered proteins.Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands.Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapiesStructural basis for Aβ1–42 toxicity inhibition by Aβ C-terminal fragments: discrete molecular dynamics study.Aminostyrylbenzofuran directly reduces oligomeric amyloid-β and reverses cognitive deficits in Alzheimer transgenic mice
P2860
Q22241945-5D9B4CBD-2165-409F-993E-1B92112EF7C5Q24645994-42808709-3DBA-455B-B8ED-3078666BDCECQ24675823-4686E43E-C75C-4B8D-98E3-2199230B4A2CQ26995918-141A79F7-2E76-4858-B7B9-D5E1529C9AC2Q27001177-9CDBA43E-ECD8-4103-A0C4-11069ECF7883Q27316634-9AB5CAFB-EC52-4A6F-9F60-A80A835BFE9BQ28081678-BA178C1B-3A54-45A8-BF1F-57D772C5C593Q28259424-8B6B9A4C-272A-4114-A4F0-96504B686677Q28477368-1B312950-C893-4E47-A6D5-F589C1A217A8Q28487382-3AE1D9E9-27BC-4CFA-A8E5-B5B9C93600E3Q28552895-79DA63C8-812D-4D38-9DB0-7C883D62C0D8Q28740942-B6B57AAA-F560-4063-B3BE-7477D1AC5C0DQ29999197-9D1979BE-D467-4E1B-8F0E-4C44D397F4D0Q30250076-96507075-D05B-4090-B1C8-C4AAF350726DQ30423892-5F0A6157-2760-471A-B798-51B4522D4780Q30483651-18458D6D-31A3-4351-B092-32DC7C6F5832Q30488155-4F5BC123-FEB2-4036-B913-BE358A41B959Q30491245-70489A85-B460-44F5-ADD2-A721F7B44924Q30492766-2EA64E3E-41B5-422E-B0D5-9079165A0855Q30493684-36CBB95A-BD8F-4849-A07F-D14A7D5DAA76Q30494177-B8704DCB-A6F9-4E79-9CAD-D22AD7EEA731Q30497187-9CEAAEF9-997A-4D88-B8F0-02B25A988703Q30676660-16B92994-89E0-48BF-B69C-36FEA56B18DFQ30855109-BB4795AC-32A9-4C95-9649-5938FF36DBEEQ33392254-96191BA2-7164-4298-BB77-D6D69CB86824Q33558132-9CB9BB62-1EC7-4FD6-A357-60CA8E689F9BQ33582089-BC6D9CDE-A19B-4DD1-8762-42EAA60904DEQ33592446-5020D91E-0C39-4166-A58F-EFC331C274CAQ33797754-29686F0C-908C-48DC-8A0D-704E97F9E682Q33800962-0EEBFA0A-E18F-4080-AFB6-4282310D0F06Q33829008-35163472-58D1-4C1E-A675-516DC1D0B75EQ33836947-2547C7A6-12C8-477B-916D-5A9524774143Q33975871-87B73FEF-CAE0-423D-BE8F-EEBEC7F53182Q33979228-0E35E568-6D33-4023-A0B2-28C07998B004Q34014237-5DD3934D-8360-4D6A-9D61-25A884D650EFQ34417638-BBD09917-7C0C-4A59-B30D-BAD8E633C2B6Q34594159-7B107EC6-6F33-4E8C-B67E-79DDDF680DCCQ34974167-14BA9FD3-2A44-4323-BB8B-7AA3576B022DQ35072878-B5B79F17-0917-435A-82D1-1C049FCE503BQ35156207-89427048-772F-4FBE-8354-1CF3C6FE82B5
P2860
Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cyclohexanehexol inhibitors of ...... er phenotype in a mouse model.
@ast
Cyclohexanehexol inhibitors of ...... er phenotype in a mouse model.
@en
type
label
Cyclohexanehexol inhibitors of ...... er phenotype in a mouse model.
@ast
Cyclohexanehexol inhibitors of ...... er phenotype in a mouse model.
@en
prefLabel
Cyclohexanehexol inhibitors of ...... er phenotype in a mouse model.
@ast
Cyclohexanehexol inhibitors of ...... er phenotype in a mouse model.
@en
P2093
P2860
P356
P1433
P1476
Cyclohexanehexol inhibitors of ...... mer phenotype in a mouse model
@en
P2093
Amie L Phinney
Audrey A Darabie
David Westaway
Fusheng Chen
Howard T J Mount
Janet E French
JoAnne McLaurin
Julian E Cousins
Mark H L Lambermon
Mary E Brown
P2860
P2888
P304
P356
10.1038/NM1423
P407
P577
2006-06-11T00:00:00Z